. 2014 Jul 18;124(11):1715–1726. doi: 10.1182/blood-2014-02-558296

Table 1.

Circulating complement profile in aHUS patients

Complement parameters	Disease phase	Overall	Mutations or anti-CFH Ab	No mutations
Reduced C3 serum levels (83-180 mg/dL)^*	Acute^†	10 (18)	5 (9)	5 (9)
Reduced C3 serum levels (83-180 mg/dL)^*	Remission^‡	15 (32)	11 (25)	4 (7)
Increased C5a plasma levels (1.9-13.1 ng/mL)^*	Acute^†	9 (19)	3 (10)	6 (9)
Increased C5a plasma levels (1.9-13.1 ng/mL)^*	Remission^‡	21 (36)	15 (27)	6 (9)
Increased SC5b-9 plasma levels (127-400 ng/mL)^*	Acute^†	10 (19)	4 (10)	6 (9)
Increased SC5b-9 plasma levels (127-400 ng/mL)^*	Remission^‡	23 (36)	20 (27)	3 (9)

Ab, antibody.

Limits of normal ranges (as defined in supplemental “Methods”). In parentheses are the numbers of patients for whom data were available, and outside the parentheses are the numbers of patients with reduced C3 or increased C5a or SC5b-9 levels.

^†

One patient was receiving eculizumab at the time of the test.

^‡

Eight patients were receiving eculizumab at the time of the tests.